JP2016528295A - Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 - Google Patents

Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 Download PDF

Info

Publication number
JP2016528295A
JP2016528295A JP2016536456A JP2016536456A JP2016528295A JP 2016528295 A JP2016528295 A JP 2016528295A JP 2016536456 A JP2016536456 A JP 2016536456A JP 2016536456 A JP2016536456 A JP 2016536456A JP 2016528295 A JP2016528295 A JP 2016528295A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tβrii
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016536456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528295A5 (enExample
Inventor
ラビンドラ クマール，
ラビンドラ クマール，
アシャ グリンバーグ，
アシャ グリンバーグ，
ダイアン エス． サコ，
ダイアン エス． サコ，
ロズリーヌ カストンギー，
ロズリーヌ カストンギー，
リタ スティーブス，
リタ スティーブス，
Original Assignee
アクセルロン ファーマ， インコーポレイテッド
アクセルロン ファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ， インコーポレイテッド, アクセルロン ファーマ， インコーポレイテッド filed Critical アクセルロン ファーマ， インコーポレイテッド
Publication of JP2016528295A publication Critical patent/JP2016528295A/ja
Publication of JP2016528295A5 publication Critical patent/JP2016528295A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
JP2016536456A 2013-08-22 2014-08-21 Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 Withdrawn JP2016528295A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361868713P 2013-08-22 2013-08-22
US61/868,713 2013-08-22
US201361906270P 2013-11-19 2013-11-19
US61/906,270 2013-11-19
US201361906849P 2013-11-20 2013-11-20
US61/906,849 2013-11-20
PCT/US2014/052130 WO2015027082A1 (en) 2013-08-22 2014-08-21 Tgf-beta receptor type ii variants and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149750A Division JP2019194270A (ja) 2013-08-22 2019-08-19 Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用

Publications (2)

Publication Number Publication Date
JP2016528295A true JP2016528295A (ja) 2016-09-15
JP2016528295A5 JP2016528295A5 (enExample) 2017-09-28

Family

ID=52480573

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016536456A Withdrawn JP2016528295A (ja) 2013-08-22 2014-08-21 Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
JP2019149750A Withdrawn JP2019194270A (ja) 2013-08-22 2019-08-19 Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
JP2021079785A Pending JP2021112212A (ja) 2013-08-22 2021-05-10 Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
JP2023199004A Pending JP2024015040A (ja) 2013-08-22 2023-11-24 Ｔｇｆ－ベータ受容体ｉｉ型変異体およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019149750A Withdrawn JP2019194270A (ja) 2013-08-22 2019-08-19 Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
JP2021079785A Pending JP2021112212A (ja) 2013-08-22 2021-05-10 Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
JP2023199004A Pending JP2024015040A (ja) 2013-08-22 2023-11-24 Ｔｇｆ－ベータ受容体ｉｉ型変異体およびその使用

Country Status (8)

Country Link
US (6) US20150056199A1 (enExample)
EP (2) EP3036262A4 (enExample)
JP (4) JP2016528295A (enExample)
CN (2) CN116655801A (enExample)
AU (2) AU2014308751B2 (enExample)
CA (1) CA2921805C (enExample)
HK (2) HK1225742A1 (enExample)
WO (1) WO2015027082A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537449A (ja) * 2016-11-19 2019-12-26 ポテンザ セラピューティックス インコーポレイテッド 抗ｇｉｔｒ抗原結合タンパク質およびその使用方法
JP2020518246A (ja) * 2017-05-04 2020-06-25 アクセルロン ファーマ， インコーポレイテッド Ｔｇｆベータ受容体ｉｉ型融合タンパク質およびその使用
JP2020519289A (ja) * 2017-05-12 2020-07-02 江蘇恒瑞医薬股▲ふん▼有限公司 ＴＧＦ−β受容体含有融合タンパク質およびそれらの医薬的用途
JP2021512919A (ja) * 2018-02-09 2021-05-20 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
JP2022512862A (ja) * 2018-11-09 2022-02-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用
JP2023500066A (ja) * 2019-10-23 2023-01-04 キュー バイオファーマ，インコーポレーテッド ＴＧＦ－βポリペプチド

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
SG10201707855YA (en) 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP4417255A3 (en) 2013-11-21 2024-10-23 The Brigham and Women's Hospital Inc. Compositions and methods for treating pulmonary hypertension
WO2016019368A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
CA2964808C (en) 2014-10-30 2023-06-27 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
EP3280727B1 (en) * 2015-04-06 2021-02-17 Acceleron Pharma Inc. Single-arm type i and type ii receptor fusion proteins and uses thereof
KR101706462B1 (ko) * 2015-07-09 2017-02-14 부산대학교 산학협력단 Nag-1 억제제를 유효성분으로 포함하는 난소암 환자의 항암제 내성 억제용 약학조성물
EP4218792A1 (en) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
EP3344660B1 (en) * 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
WO2017152105A1 (en) * 2016-03-04 2017-09-08 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
US20190248852A1 (en) 2016-05-24 2019-08-15 Novo Nordisk A/S MIC-1 Compounds and Use Thereof
MX2019003445A (es) * 2016-09-27 2019-09-26 Epicentrx Inc Proteinas de fusion inmunomoduladoras.
CA3039525A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
US20190352373A1 (en) * 2017-01-25 2019-11-21 Tessa Therapeutics Pte. Ltd. TGF-ß DECOY RECEPTOR
CN110573532B (zh) * 2017-03-02 2024-04-16 加拿大国家研究委员会 TGF-β 受体胞外域融合分子及其用途
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
MX2020003672A (es) 2017-09-27 2020-08-03 Epicentrx Inc Proteinas de fusion inmunomoduladora.
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
MX2020009394A (es) 2018-03-09 2021-01-15 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos.
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
JP2021522795A (ja) 2018-05-03 2021-09-02 アクセルロン ファーマ インコーポレイテッド ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用
WO2019246563A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
CA3105750A1 (en) 2018-07-09 2020-01-16 Precigen, Inc. Fusion constructs and methods of using thereof
CN109097461B (zh) * 2018-09-06 2021-07-30 北京中关村生命科学园生物医药科技孵化有限公司 一种心肌病相关基因检测试剂及其应用
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
GB2599227B (en) 2019-02-21 2024-05-01 Marengo Therapeutics Inc Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
CN113544149B (zh) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
KR20250095757A (ko) 2019-06-21 2025-06-26 카이트 파마 인코포레이티드 TGF-β 수용체 및 이의 사용 방법
WO2020263312A1 (en) * 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
US11802145B2 (en) 2019-10-21 2023-10-31 Nanjing Leads Biolabs Co., Ltd. Recombinant protein targeting PD-1 and TGFß
WO2021092079A1 (en) * 2019-11-05 2021-05-14 Acceleron Pharma Inc. Treatments for systemic sclerosis
TWI772984B (zh) * 2019-11-27 2022-08-01 大陸商上海岸邁生物科技有限公司 TGFβ/PD-L1雙特異性結合蛋白
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
JP2023523011A (ja) 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
KR20230003114A (ko) * 2020-04-28 2023-01-05 사이노셀테크 엘티디. TGFβR2 세포외 도메인 절단된 분자, TGFβR2 세포외 도메인 절단된 분자와 항-EGFR 항체의 융합 단백질, 및 융합 단백질의 항종양 용도
CN113754777A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗PD-L1/TGF-β融合蛋白
WO2022011256A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
US11028174B1 (en) 2020-07-28 2021-06-08 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting PD-L1 and TGF-β
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN112215941B (zh) * 2020-09-04 2021-06-25 北京科技大学 一种基于微分几何的主动脉扭曲的评估方法及系统
WO2022068894A1 (zh) * 2020-09-30 2022-04-07 上海齐鲁制药研究中心有限公司 同时靶向pd-l1和vegf的双功能分子及其医药用途
WO2022105751A1 (zh) * 2020-11-19 2022-05-27 信达生物制药(苏州)有限公司 TGFβRII融合蛋白以及其用途
US20240000891A1 (en) * 2020-12-08 2024-01-04 The Board Of Trustees Of The Leland Stanford Junior University Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
EP4351723A4 (en) * 2021-06-11 2025-04-16 Acceleron Pharma, Inc. ACTRII PROTEINS AND THEIR USES
CN115746124A (zh) * 2021-09-02 2023-03-07 广东菲鹏制药股份有限公司 TGFβRII突变体及其应用
EP4469489A1 (en) 2022-01-28 2024-12-04 35Pharma Inc. Activin receptor type iib variants and uses thereof
JP2024096518A (ja) * 2023-01-03 2024-07-16 エフビーデー バイオロジクス リミテッド 操作されたｔｇｆｂｒｉｉバリアント及びその使用方法
EP4653010A1 (en) 2024-05-14 2025-11-26 35Pharma Inc. Activin receptor type iib traps for use in improving body composition

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515360A (ja) * 1997-04-18 2001-09-18 バイオジェン，インコーポレイテッド ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質
JP2008501716A (ja) * 2004-06-04 2008-01-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
JP2011520793A (ja) * 2008-05-02 2011-07-21 アクセルロン ファーマ， インコーポレイテッド 血管新生および周皮細胞組成物を調節するための方法および組成物
JP2011525917A (ja) * 2008-06-26 2011-09-29 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストを投薬する方法および処置される患者をモニターする方法
JP2011526794A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＧＦ−βアンタゴニスト多重標的結合性分子
JP2012522507A (ja) * 2009-03-30 2012-09-27 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
WO2013000234A1 (en) * 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd A novel recomnimant bifunctional fusion protein and its preparation and use
JP2013521311A (ja) * 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
ZA914750B (en) 1990-06-20 1992-03-25 Bristol Myers Squibb Co Methods of modulating blood pressure using tgf-beta and antagonists thereof
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
ES2191007T3 (es) 1991-10-31 2003-09-01 Whitehead Biomedical Inst Receptor tipo iii de tgf-beta, cdna que lo codifica y sus usos.
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
US5543143A (en) 1992-03-06 1996-08-06 Corixa Corporation Method for activating macrophages/monocytes
ES2174868T3 (es) * 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
ATE355369T1 (de) 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5866323A (en) 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
ATE352638T1 (de) 1995-04-11 2007-02-15 Gen Hospital Corp REVERSE ßTWO-HYBRIDß-SYSTEME
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
ZA988461B (en) 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
EP1087998A1 (en) 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
WO2001066140A1 (en) 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
US20040234967A1 (en) 2000-03-24 2004-11-25 Moskowitz David W. Diagnostic polymorphisms of tgf-beta-rii promoter
US20030028905A1 (en) 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
EP1478354A4 (en) 2002-01-22 2008-09-24 Genzyme Corp USE OF TGF-BETA ANTAGONISTS IN THE TREATMENT OR PREVENTION OF CHRONIC RELEASE OF TRANSPLANT
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
AU2003297460A1 (en) 2002-12-19 2004-07-14 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
US20060286105A1 (en) 2003-04-30 2006-12-21 Steven Ledbetter Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20060229266A1 (en) 2003-08-13 2006-10-12 Kumar Nalin M Silencing of tgf-beta receptor type II expression by sirna
BRPI0413757A (pt) 2003-08-22 2006-10-31 Boehringer Ingelheim Pharma métodos para o tratamento de copd e da hipertensão pulmonar
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7786261B2 (en) 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
JP2008513542A (ja) 2004-09-22 2008-05-01 ジェンザイム・コーポレイション 免疫抑制剤の腎毒性を制限するためのＴＧＦ−βアンタゴニストの使用
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
EP1809324A4 (en) 2004-10-13 2009-02-25 Univ Ohio State Res Found METHOD FOR TREATING OR PREVENTING VIRAL LMPMPHOPROIBLE DISEASES
PT3520815T (pt) 2005-02-08 2022-02-02 Genzyme Corp Anticorpos contra tgfbeta
JP5342834B2 (ja) 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
ITMI20060181A1 (it) 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
EP2230252A1 (en) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation of endothelial thromboresistance
US20100003256A1 (en) 2006-06-05 2010-01-07 Novartis Ag Use of TGF-Beta Antagonists in Treatment of Parathyroid-Related Disorders
CN104645328A (zh) 2006-10-03 2015-05-27 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
EP2578684B1 (en) 2007-03-19 2016-02-24 National Research Council Of Canada Antagonists of ligands and uses thereof
WO2008157367A1 (en) 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
AU2008289135B2 (en) 2007-08-22 2012-02-23 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
WO2009092087A2 (en) 2008-01-18 2009-07-23 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, and modulation of human th17 cells
US8658135B2 (en) * 2008-03-19 2014-02-25 National Research Council Of Canada Antagonists of ligands and uses thereof
US20110104121A1 (en) 2008-05-21 2011-05-05 Wira Charles R Female Reproductive Tract and Anal Prophylaxes
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
US20120010178A1 (en) 2008-10-21 2012-01-12 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US20120114640A1 (en) 2009-05-08 2012-05-10 Kulkarni Ashok B MODULATION OF THE TGF- ß AND PI3K/AKT PATHWAYS IN THE DIAGNOSIS AND TREATMENT OF SQUAMOUS CELL CARCINOMA
WO2011088148A1 (en) 2010-01-12 2011-07-21 Isis Pharmaceuticals, Inc. Modulation of transforming growth factor-beta 1 expression
CN101852804B (zh) * 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
KR101939965B1 (ko) 2010-09-01 2019-01-18 젠자임 코포레이션 ＴＧＦ－β 길항제를 이용한 심근경색증의 치료
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
US8800906B2 (en) 2010-12-27 2014-08-12 The Board Of Trustees Of The Leland Stanford Junior University Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
BR112013016917A2 (pt) 2011-01-06 2017-04-04 Glaxo Group Ltd ligantes que ligam receptor de tgf-beta ii.
CA2833747C (en) 2011-04-20 2022-10-18 Asya Grinberg Endoglin polypeptides and uses thereof
WO2013012648A1 (en) * 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
EP2739645B1 (en) 2011-08-01 2018-12-19 Tufts Medical Center, Inc. Endoglin-specific antibody for use in a method of treating heart failure and related conditions
WO2013059879A1 (en) 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CA2947354C (en) 2012-04-30 2024-03-19 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
EP2849762A4 (en) 2012-05-16 2016-02-24 Aadigen Llc MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY DISORDERS
US9783604B2 (en) 2013-03-11 2017-10-10 Genzyme Corporation Engineered anti-TGF-beta antibodies and antigen-binding fragments
MY186864A (en) 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
JP6578271B2 (ja) 2013-04-17 2019-09-18 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 免疫抑制ＴＧＦ−βシグナルコンバーター
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP4417255A3 (en) 2013-11-21 2024-10-23 The Brigham and Women's Hospital Inc. Compositions and methods for treating pulmonary hypertension
NZ721364A (en) 2014-02-10 2023-04-28 Merck Patent Gmbh Targeted tgfβ inhibition
JP6773563B2 (ja) 2014-05-18 2020-10-21 ザ チルドレンズ メディカル センター コーポレーション エキソソームに関連する方法および組成物
RU2016147122A (ru) 2014-06-13 2018-07-16 Новартис Аг Применение серелаксина для снижения gdf-15
WO2016019368A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
EP4218792A1 (en) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
EP3344660B1 (en) 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
WO2017134592A1 (en) 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
US20180118832A1 (en) 2016-08-12 2018-05-03 Merck Patent Gmbh Combination therapy for cancer
MX2019003445A (es) 2016-09-27 2019-09-26 Epicentrx Inc Proteinas de fusion inmunomoduladoras.
WO2018129331A1 (en) 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
CN110573532B (zh) 2017-03-02 2024-04-16 加拿大国家研究委员会 TGF-β 受体胞外域融合分子及其用途
DK3628049T3 (da) 2017-05-04 2023-08-14 Acceleron Pharma Inc Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
WO2019157342A1 (en) 2018-02-09 2019-08-15 Acceleron Pharma Inc. Methods for treating heterotopic ossification

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515360A (ja) * 1997-04-18 2001-09-18 バイオジェン，インコーポレイテッド ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質
JP2008501716A (ja) * 2004-06-04 2008-01-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
JP2011520793A (ja) * 2008-05-02 2011-07-21 アクセルロン ファーマ， インコーポレイテッド 血管新生および周皮細胞組成物を調節するための方法および組成物
JP2011525917A (ja) * 2008-06-26 2011-09-29 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストを投薬する方法および処置される患者をモニターする方法
JP2011526794A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＧＦ−βアンタゴニスト多重標的結合性分子
JP2012522507A (ja) * 2009-03-30 2012-09-27 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
JP2013521311A (ja) * 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
WO2013000234A1 (en) * 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd A novel recomnimant bifunctional fusion protein and its preparation and use

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537449A (ja) * 2016-11-19 2019-12-26 ポテンザ セラピューティックス インコーポレイテッド 抗ｇｉｔｒ抗原結合タンパク質およびその使用方法
JP2020518246A (ja) * 2017-05-04 2020-06-25 アクセルロン ファーマ， インコーポレイテッド Ｔｇｆベータ受容体ｉｉ型融合タンパク質およびその使用
JP2023055827A (ja) * 2017-05-04 2023-04-18 アクセルロン ファーマ インコーポレイテッド Ｔｇｆベータ受容体ｉｉ型融合タンパク質およびその使用
JP7267664B2 (ja) 2017-05-04 2023-05-02 アクセルロン ファーマ インコーポレイテッド Ｔｇｆベータ受容体ｉｉ型融合タンパク質およびその使用
JP2020519289A (ja) * 2017-05-12 2020-07-02 江蘇恒瑞医薬股▲ふん▼有限公司 ＴＧＦ−β受容体含有融合タンパク質およびそれらの医薬的用途
JP7264827B2 (ja) 2017-05-12 2023-04-25 江蘇恒瑞医薬股▲ふん▼有限公司 ＴＧＦ－β受容体含有融合タンパク質およびそれらの医薬的用途
JP2021512919A (ja) * 2018-02-09 2021-05-20 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
JP7654402B2 (ja) 2018-02-09 2025-04-01 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
JP2022512862A (ja) * 2018-11-09 2022-02-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用
JP7436477B2 (ja) 2018-11-09 2024-02-21 ジエンス ヘンルイ メデイシンカンパニー リミテッド ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用
JP2023500066A (ja) * 2019-10-23 2023-01-04 キュー バイオファーマ，インコーポレーテッド ＴＧＦ－βポリペプチド
JP7756638B2 (ja) 2019-10-23 2025-10-20 キュー バイオファーマ，インコーポレーテッド ＴＧＦ－βポリペプチド

Also Published As

Publication number Publication date
US20190284257A1 (en) 2019-09-19
US20180179261A1 (en) 2018-06-28
EP3036262A4 (en) 2017-03-01
AU2020203514B2 (en) 2022-06-16
EP3705498A1 (en) 2020-09-09
US9809637B2 (en) 2017-11-07
JP2024015040A (ja) 2024-02-01
HK1225742A1 (zh) 2017-09-15
HK1225740A1 (zh) 2017-09-15
US20160376341A1 (en) 2016-12-29
JP2019194270A (ja) 2019-11-07
AU2014308751A1 (en) 2016-03-17
US20200157182A1 (en) 2020-05-21
AU2020203514A1 (en) 2020-06-18
US11008377B2 (en) 2021-05-18
CN105658672A (zh) 2016-06-08
WO2015027082A1 (en) 2015-02-26
US20150056199A1 (en) 2015-02-26
CA2921805A1 (en) 2015-02-26
US20210230252A1 (en) 2021-07-29
US10981973B2 (en) 2021-04-20
JP2021112212A (ja) 2021-08-05
AU2014308751B2 (en) 2020-03-05
CA2921805C (en) 2023-03-07
EP3036262A1 (en) 2016-06-29
CN116655801A (zh) 2023-08-29
US10316076B2 (en) 2019-06-11

Similar Documents

Publication Publication Date Title
JP2019194270A (ja) Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
JP7267664B2 (ja) Ｔｇｆベータ受容体ｉｉ型融合タンパク質およびその使用
JP6348448B2 (ja) Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP6250533B2 (ja) エンドグリンポリペプチドおよびその使用
US8642031B2 (en) Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
EP3398966A1 (en) Methods and compositions for modulating angiogenesis and pericyte composition
CN104379159A (zh) 变体激活素受体多肽,单独或与化疗结合,及其用途
JP2019196364A (ja) 線維性疾患を処置するためのエンドグリンポリペプチド
HK40037295A (en) Tgf-beta receptor type ii variants and uses thereof
HK40099479A (en) Tgf-beta receptor type ii fusion proteins and uses thereof
HK40025678A (en) Tgf-beta receptor type ii fusion proteins and uses thereof
HK40025678B (en) Tgf-beta receptor type ii fusion proteins and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180613

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190927

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191115

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200827